These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 4900504)
1. [Clinical study of various compounds of PAS]. Potworowska M; Wareska W; Lachowicz E; Pecyna-Sielewicz J; Ambroziak-Miller M Gruzlica; 1969 Jul; 37(7):673-80. PubMed ID: 4900504 [No Abstract] [Full Text] [Related]
2. [Studies on the metabolism of para-aminosalicylic acid in the body. VI. Absorption, tolerance and therapeutic effect of Napashin in double gastro-enteric coating]. Nikodemowicz E; Owsiñski M; Kamiñska M; Ostrowska A; Rapf T Gruzlica; 1971 Nov; 39(11):1113-21. PubMed ID: 5137653 [No Abstract] [Full Text] [Related]
3. [Clinical evaluation of Rifampicin in pulmonary tuberculosis. 2. A controlled trial on the clinical effects of chemotherapy with Rifampicin-INH-PAS and SM-INH-PAS for treatment of original cases of pulmonary tuberculosis]. Donomae I; Fujita S; Gomi J; Hibino S; Horai Z Kekkaku; 1970 Aug; 45(8):257-62. PubMed ID: 4918166 [No Abstract] [Full Text] [Related]
4. [Early results of a modified treatment of 100 cases of newly detected tuberculosis with standard drugs with the substitution of PAS for ethionamide]. Piekarniak K; Danilczuk R; Martyniak K; Wyczółkowski M Gruzlica; 1973 Aug; 41(8):837-43. PubMed ID: 4755391 [No Abstract] [Full Text] [Related]
5. The need for new antituberculous drugs. Dahlström G Scand J Respir Dis Suppl; 1969; 69():11-3. PubMed ID: 4906370 [No Abstract] [Full Text] [Related]
6. [Comparative studies of tolerance of pasomycin, streptomycin and pas in ambulatory patients]. Rudoĭ NM; Fisher IuIa; Bril LN Antibiotiki; 1972 Jan; 17(1):76-9. PubMed ID: 5019440 [No Abstract] [Full Text] [Related]
7. Madras Study of intermittent oral chemotherapy. Tripathy SP Bull Int Union Tuberc; 1972 Feb; 47():30-6. PubMed ID: 5077117 [No Abstract] [Full Text] [Related]
8. [Para-aminosalicylic acid metabolism in the body. VII. Resorption and tolerance of calcium-PAS compound and early results of treatment of pulmonary tuberculosis]. Owsiński J; Kamińska M; Ostrowska A; Rapf T Gruzlica; 1972 Jul; 40(7):635-7. PubMed ID: 5053842 [No Abstract] [Full Text] [Related]
9. [Studies on the metabolism of para-aminosalicylic acid in the body. IV. Effect of sodium salt of para-animosalicylic acid administered orally in coated tablets soluble in the intestine on the bacteriostatic level and on drug tolerance]. Hornung S; Nilodemowicz E; Owsiński J; Rapf T Gruzlica; 1967 Jul; 35(7):657-64. PubMed ID: 4865322 [No Abstract] [Full Text] [Related]
10. [Isoniazide-tiocarlide combination or DAT in the treatment of pulmonary tuberculosis. Comparison with isoniazide-PAS combination and especially BPAS]. Meyer A; Nadjar-Fossé G Rev Tuberc Pneumol (Paris); 1968; 32(3):371-80. PubMed ID: 5693998 [No Abstract] [Full Text] [Related]
11. Tolerance to ethionamid and PAS in original treatment of tuberculous patients. Verbist L; Prignot J; Cosemans J; Gyselen A Scand J Respir Dis; 1966; 47(4):225-35. PubMed ID: 5182290 [No Abstract] [Full Text] [Related]
12. [Active fraction of isonicotinic acid hydrazide in the blood of tuberculosis patients during its combined use with PAS]. Dudchik GKh; Bilyk MA Vrach Delo; 1981 Feb; (2):77-8. PubMed ID: 7222619 [No Abstract] [Full Text] [Related]
13. [Reduction of fresh forms of pulmonary tuberculosis by the classical treatment and by combined antibiotics including rifampicin (comparative study of a personal survey)]. Weill G; Lévy A; Guignon JP; Lecoq H; Friess JM; Maman P Rev Tuberc Pneumol (Paris); 1969 Dec; 33(8):1119-25. PubMed ID: 4916253 [No Abstract] [Full Text] [Related]
14. [Effectiveness and possibilities of application to ambulatory patients in our region of a pulmonary tuberculosis therapy by the intermittent administration (I.V.) of the triple association isoniazid-streptomycin-PAS (preliminary results after a year)]. Burghard G; Petitjean R; Schranz J; Scherrer B Rev Tuberc Pneumol (Paris); 1970; 34(3):439-53. PubMed ID: 5515514 [No Abstract] [Full Text] [Related]
15. [Early results of intermittent and continuous modified treatment with standard drugs and limited dosage of PAS in previously untreated pulmonary tuberculosis. Preliminary report]. Stopczyk J; Niemirowska H; Pecyna-Sielewicz J; Janowiec M Gruzlica; 1970; 38(7):705-18. PubMed ID: 5453680 [No Abstract] [Full Text] [Related]
16. [Clinical tolerance of rifampycin administered alone or in combination with other antitubercular drugs]. Carratù L; Sonaglioni F; Natali P Arch Tisiol Mal Appar Respir; 1968 May; 23(5):399-410. PubMed ID: 5306592 [No Abstract] [Full Text] [Related]
17. [The para-aminosalicylic acid (PAS) level of the venous blood in patients after the administration of various PAS preparations for pulmonary tuberculosis]. Kreukniet J; Tasman A; Bangma PJ Ned Tijdschr Geneeskd; 1965 Sep; 109(38):1760-1. PubMed ID: 5317952 [No Abstract] [Full Text] [Related]
18. [The role of PAS infusions in modern chemotherapy of pulmonary tuberculosis (author's transl)]. Opl G Prax Pneumol; 1974 Jan; 28(1):30-3. PubMed ID: 4815709 [No Abstract] [Full Text] [Related]
19. [Preliminary findings and considerations on primary resistance to SM, INI, and PAS in the Provincial Antitubercular Association of Naples]. Romano S; Grella G Rass Int Clin Ter; 1966 Dec; 46(23):1311-6. PubMed ID: 5997869 [No Abstract] [Full Text] [Related]
20. [Results of routine treatment of pulmonary tuberculosis patients treated for the 1st time]. Bernard E; Abadi O; Pretet S Rev Tuberc Pneumol (Paris); 1969 Nov; 33(7):967-74. PubMed ID: 5402999 [No Abstract] [Full Text] [Related] [Next] [New Search]